OBJECTIVE: A meta-analysis of published randomized controlled trials investigating the longterm effect of dexamethasone on the nervous system of preterm infants.DATA SOURCES: Online literature retrieval was conducted using The Cochrane Library(from January 1993 to June 2013), EMBASE(from January 1980 to June 2013), MEDLINE(from January 1963 to June 2013), OVID(from January 1993 to June 2013), Springer(from January 1994 to June 2013) and Chinese Academic Journal Full-text Database(from January 1994 to June 2013). Key words were preterm infants and dexamethasone in English and Chinese.STUDY SELECTION: Selected studies were randomized controlled trials assessing the effect of intravenous dexamethasone in preterm infants. The quality of the included papers was evaluated and those without the development of the nervous system and animal experiments were excluded. Quality assessment was performed through bias risk evaluation in accordance with Cochrane Handbook 5.1.0 software in the Cochrane Collaboration. The homogeneous studies were analyzed and compared using Revman 5.2.6 software, and then effect model was selected and analyzed. Those papers failed to be included in the meta-analysis were subjected to descriptive analysis.MAIN OUTCOME MEASURES: Nervous system injury in preterm infants.RESULTS: Ten randomized controlled trials were screened, involving 1,038 subjects. Among them 512 cases received dexamethasone treatment while 526 cases served as placebo control group and blank control group. Meta-analysis results showed that the incidence of cerebral palsy, visual impairment and hearing loss in preterm infants after dexamethasone treatment within 7 days after birth was similar to that in the control group(RR = 1.47, 95%CI: 0.97–2.21; RR = 1.46, 95%CI: 0.97–2.20; RR = 0.80, 95%CI: 0.54–1.18; P > 0.05), but intelligence quotient was significantly decreased compared with the control group(MD =-3.55, 95%CI:-6.59 to-0.51; P = 0.02). Prete rm infants treated with dexamethasone 7 days after birth demonstrated an incidence of cerebral palsy and visual impairment, and changes in intelligence quotient similar to those in the control group(RR = 1.26, 95%CI: 0.89–1.79; RR = 1.37, 95%CI: 0.73–2.59; RR = 0.53, 95%CI: 0.32–0.89; RR = 1.66, 95%CI:-4.7 to 8.01; P > 0.05). However, the incidence of hearing loss was significantly increased compared with that in the control group(RR = 0.53, 95%CI: 0.32–0.89; P = 0.02).CONCLUSION: Dexamethasone may affect the intelligence of preterm infants in the early stages after birth, but may lead to hearing impairment at later stages after birth. More reliable conclusions should be made through large-size, multi-center, well-designed randomized controlled trials. OBJECTIVE: A meta-analysis of published randomized controlled trials investigating the longterm effect of dexamethasone on the nervous system of preterm infants. DATA SOURCES: Online literature retrieval was conducted using The Cochrane Library (from January 1993 to June 2013), EMBASE (from January 1980 to June 2013), MEDLINE (from January 1963 to June 2013), OVID (from January 1993 to June 2013), Springer (from January 1994 to June 2013) and Chinese Academic Journal Full-text Database (from January 1994 to June 2013) ) Key words were preterm infants and dexamethasone in English and Chinese. STUDY SELECTION: Selected studies were randomized controlled trials assessing the effect of intravenous dexamethasone in preterm infants. The quality of the included papers was evaluated and those without the development of the nervous system. and animal experiments were excluded. Quality assessment was performed through bias risk evaluation in accordance with Cochrane Handbook 5.1.0 software in the Cochrane Collaboration. The homogeneous studies were analyzed and compared using Revman 5.2.6 software, and then effect model was selected and analyzed. Those papers failed to be included in the meta-analysis were subjected to descriptive analysis. MAIN OUTCOME MEASURES: Nervous system injury in Preterm infants.RESULTS: Ten randomized controlled trials were screened, involving 1,038 subjects. Among them 512 cases received dexamethasone treatment while 526 cases served as placebo control group and blank control group. Meta-analysis results showed that the incidence of cerebral palsy, visual impairment and hearing loss in preterm infants after dexamethasone treatment within 7 days after birth was similar to that in the control group (RR = 1.47, 95% CI: 0.97-2.21; RR = 1.46, 95% CI: 0.97-2.20; RR = 0.80 , 95% CI: 0.54-1.18; P> 0.05), but the intelligence quotient was significantly decreased compared with the control group (MD = -3.55, 95% CI: -6.59 to-0.51; with dexam ethasone 7 days after birth demonstrated an incidence of cerebral palsy and visual impairment, and changes in intelligence quotient similar to those in the control group (RR = 1.26, 95% CI: 0.89-1.79; RR = 1.37, 95% CI: 0.73- 2.59; RR = 0.53, 95% CI: 0.32-0.89; RR = 1.66, 95% CI: -4.7 to 8.01; P> 0.05). However, the incidence of hearing loss was significantly increased compared to that in the control group ( RR = 0.53, 95% CI: 0.32-0.89; P = 0.02) .CONCLUSION: Dexamethasone may affect the intelligence of preterm infants in the early stages after birth, but may lead to hearing impairment at later stages after birth. be made through large-size, multi-center, well-designed randomized controlled trials.